Targeting Kv7 Potassium Channels for Epilepsy
Open accessThe DOI matches its Crossref record; 179 of the 179 references it cites were found in a registry or an index.
Abstract
Voltage-gated Kv7 potassium channels, particularly Kv7.2 and Kv.7.3 channels, play a critical role in modulating susceptibility to seizures, and mutations in genes that encode these channels cause heterogeneous epilepsy phenotypes. On the basis of this evidence, activation of Kv7.2 and Kv.7.3 channels has long been considered an attractive target in the search for novel antiseizure medications. Ezogabine (retigabine), the first Kv7.2/3 activator introduced in 2011 for the treatment of focal seizures, was withdrawn from the market in 2017 due to declining use after discovery of its association with pigmentation changes in the retina, skin, and mucosae. A novel formulation of ezogabine for pediatric use (XEN496) has been recently investigated in children with KCNQ2-related developmental and epileptic encephalopathy, but the trial was terminated prematurely for reasons unrelated to safety. Among novel Kv7.2/3 openers in clinical development, azetukalner has shown dose-dependent efficacy against drug-resistant focal seizures with a good tolerability profile and no evidence of pigmentation-related adverse effects in early clinical studies, and it is now under investigation in phase III trials for the treatment of focal seizures, generalized tonic-clonic seizures, and major depressive disorder. Another Kv7.2/3 activator, BHV-7000, has completed phase I studies in healthy subjects, with excellent tolerability at plasma drug concentrations that exceed the median effective concentrations in a preclinical model of anticonvulsant activity, but no efficacy data in patients with epilepsy are available to date. Among other Kv7.2/3 activators in clinical development as potential antiseizure medications, pynegabine and CB-003 have completed phase I safety and pharmacokinetic studies, but results have not been yet reported. Overall, interest in targeting Kv7 channels for the treatment of epilepsy and for other indications remains strong. Future breakthroughs in this area could come from exploitation of mechanistic differences in the action of Kv7 activators, and from the development of molecules that combine Kv7 activation with other mechanisms of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Hypothetical mechanism of activation of Kv7 channels by ezogabine. Only two of the four subunits forming the functional channel are shown for simplicity. (A) Under resting conditions, the S4 segment of the voltage-sensing domain (VSD) is positioned toward the intracellular side of the membrane. This configuration is stabilized by calmodulin bridging the core region at the S2–S3 linker [where phosphatidylinositol-4,5-biphosphate (PIP2) also binds] and the C-terminus at two α-helical regions denominated HA and HB. The inner pore gate (IG) is closed, the central cavity (CC) above the IG and below the selectivity filter (SF), is narrow. Although the SF is in a conductive state, no ion can flow through the pore as the IG is closed. (B) Membrane depolarization induces a vertical shift in the S4 segment, which also induces a lateral rotation and an upward motion of the S4–S5 linker. (C) S4 repositioning, and the consequent upward motion of the S4–S5 linker, bends the S6 C-terminal half of an adjacent subunit and leads to widening of the IG and an increased hydration of the CC, triggering K+ conduction. Such processes are also accompanied, and possibly facilitated, by the fact that, upon depolarization, the HA and HB helices in the proximal C-terminus, where calmodulin binds in the closed channel configuration, undergo an almost 180° rotation, causing the HA and S6 helices to join in a continuous helix and calmodulin to be released from its attachment site in the S2–S3 linker, as well as by PIP2 repositioning from the S2–S3 linker to the S4–S5 linker. The positions of the ezogabine binding sites (one per subunit) are indicated relative to the overall structure of the channel. (D) A flat ribbon representation of the ezogabine binding site in a Kv7.2 subunit. The illustration shows the ezogabine molecule and the S5 and S6 transmembrane regions from a single Kv7.2 subunit contributing to the binding site. Ionized hydrogen bonds are shown as dashed-yellow lines. The Trp236 residue, which is critical for ezogabine binding, is indicated, together with Leu299 and Ser303 also contributing to drug-channel interactions. Data are from the Protein Data Bank (7CR2) [56, 60]](https://figures.cochat.ai/paper-figures/654f6ca15dfa40f1846b1b46906384c6/targeting-kv7-potassium-channels-for-epilepsy-figure-1.jpg)

![Fig. 3 Median percent reduction from baseline in focal seizure frequency in patients included in randomized double-blind, placebo-controlled, adjunctive-therapy trials of ezogabine (EZG) in focal epilepsy. Based on data from Porter et al. [111], Brodie et al. [112], and French et al. [113]](https://figures.cochat.ai/paper-figures/003169de242c400e9178410ba6608bcd/targeting-kv7-potassium-channels-for-epilepsy-figure-3.jpg)
![Fig. 4 Responder rates (percent of patients with ≥ 50% reduction in focal seizure frequency from baseline) in patients included in randomized, double-blind, placebo-controlled, adjunctive-therapy trials of ezogabine in focal epilepsy. For the study by Porter et al. [111] responder rate was calculated over the entire double-blind treatment period (titration plus maintenance), whereas for the studies by Brodie et al. [112] and French et al. [113] the responder rates shown in the figure were calculated over the maintenance dose period only](https://figures.cochat.ai/paper-figures/719aa10d545846cbbe7b2f29e465e6ba/targeting-kv7-potassium-channels-for-epilepsy-figure-4.jpg)

![Fig. 6 Median percent reduction from baseline in focal seizure frequency (left panel) and responder rates (percent of participants with ≥ 50% reduction in focal seizure frequency from baseline, right panel) in patients included in the phase 2b randomized, double-blind, placebo-controlled, adjunctive-therapy trial of azetukalner (AZE) in focal epilepsy. Based on data from French et al. [146]](https://figures.cochat.ai/paper-figures/6892d345074d4921a56c0e9e4912a064/targeting-kv7-potassium-channels-for-epilepsy-figure-6.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chronic ezogabine is associated with dose dependent dizziness, somnolence, confusion, urinary retention, and, most notably, blue or purple pigmentation of retina, nails, and skin due to drug and metabolite accumulation in melanin rich tissues [253,258,262].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [262]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Brain-penetrant exemplars such as Lu AA41178 and SCR2682, pan-Kv7 (KCNQ2–5) potassium-channel activators, demonstrate broad antiexcitability efficacy without major off-target activity, while clinical candidates including azetukalner and BHV-7000, Kv7.2/7.3-selective channel activators, aim to retain efficacy while avoiding pigmentation and urinary liabilities associated with earlier chemotypes [”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [262]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Beyond mood, ezogabine reduces cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis and decreases seizure frequency in refractory epilepsy, demonstrating target engagement in human hyperexcitable states and supporting its transdiagnostic potential to quiet unstable circuits [256,262,263].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [262]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fisher, R. S., Boas, W. V. E., Blume, W., Elger, C., Genton, P., Lee, P., & Engel, J. (2005) · Epilepsia · doi:10.1111/j.0013-9580.2005.66104.x · Cited by 3,671 · cited 1×
“An epileptic seizure is defined as “a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain” [1].”
Beghi, E., Berg, A., Carpio, A., Forsgren, L., Hesdorffer, D. C., Hauser, W. A., Malmgren, K., Shinnar, S., Temkin, N., Thurman, D., et al. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.00273_1.x · Cited by 2,296
Coassembly of KVLQT1 and minK (IsK) proteins to form cardiac IKS potassium channel
Sanguinetti, M. C., Curran, M. E., Zou, A., Shen, J., Specter, P. S., Atkinson, D. L., & Keating, M. T. (1996) · Nature · doi:10.1038/384080a0 · Cited by 1,764
Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias
Wang, Q., Curran, M. E., Splawski, I., Burn, T. C., Millholland, J. M., VanRaay, T. J., Shen, J., Timothy, K. W., Vincent, G. M., de Jager, T., et al. (1996) · Nature Genetics · doi:10.1038/ng0196-17 · Cited by 1,759 · cited 1×
“KCNQ1 mutations are responsible for the most common form of long QT syndrome [43], an arrhythmogenic disorder predisposing to torsades de pointes and ventricular fibrillation.”
Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone
Brown, D. A., & Adams, P. R. (1980) · Nature · doi:10.1038/283673a0 · Cited by 1,444 · cited 1×
“…fEPSPs, these slow responses showed long synaptic delays (tenths to hundredths of ms), were long-lasting (many seconds) and were due to acetylcholine binding to M1, M3, or M5 muscarinic receptors, hence the name “M-current (I KM )” [24] for the K + current whose suppression generated sEPSPs [23].”
KCNQ2 and KCNQ3 Potassium Channel Subunits: Molecular Correlates of the M-Channel
Wang, H. (1998) · Science · doi:10.1126/science.282.5395.1890 · Cited by 1,294 · cited 1×
“When co-expressed in frog oocytes, KCNQ2 and KCNQ3 yield voltage-gated K + currents with biophysical and pharmacological properties identical to those of the M-current [31, 32], suggesting that the native ganglionic I KM is carried by an heterotetramer of Kv7.”
A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns
Singh, N. A., Charlier, C., Stauffer, D., DuPont, B. R., Leach, R. J., Melis, R., Ronen, G. M., Bjerre, I., Quattlebaum, T., Murphy, J. V., et al. (1998) · Nature Genetics · doi:10.1038/ng0198-25 · Cited by 1,199 · cited 2×
“The recognition that Kv7 channels determine I KM occurred after discovery of epileptogenic variants in two neuronally expressed genes, KCNQ2 [29] and KCNQ3 [30], respectively encoding Kv7.”
Hyperpolarization-Activated Cation Currents: From Molecules to Physiological Function
Robinson, R. B., & Siegelbaum, S. A. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142734 · Cited by 1,177 · cited 1×
“…(b) a recurrent neuron–astrocyte–neuron excitatory loop [9], (c) faster action potentials repolarization and sodium (Na + ) channels repriming caused by hyperactivation of BK channels [10], or (d) hyperpolarization-activated nonselective cation currents [11], resulting in secondary depolarization.”
A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family
Charlier, C., Singh, N. A., Ryan, S. G., Lewis, T. B., Reus, B. E., Leach, R. J., & Leppert, M. (1998) · Nature Genetics · doi:10.1038/ng0198-53 · Cited by 937 · cited 2×
“The recognition that Kv7 channels determine I KM occurred after discovery of epileptogenic variants in two neuronally expressed genes, KCNQ2 [29] and KCNQ3 [30], respectively encoding Kv7.”
Zuberi, S. M., Wirrell, E., Yozawitz, E., Wilmshurst, J. M., Specchio, N., Riney, K., Pressler, R., Auvin, S., Samia, P., Hirsch, E., et al. (2022) · Epilepsia · doi:10.1111/epi.17239 · Cited by 934 · cited 5×
“…frequent drug-resistant seizures (mostly with a tonic component) appearing in the first 3 months of life; abnormalities of posture, tone, or movement; developmental impairment; and an abnormal interictal electroencephalogram (EEG), which may include a burst-suppression or multifocal pattern [63].”
InfluentialSelf-citationKubisch, C., Schroeder, B. C., Friedrich, T., Lütjohann, B., El-Amraoui, A., Marlin, S., Petit, C., & Jentsch, T. J. (1999) · Cell · doi:10.1016/s0092-8674(00)80556-5 · Cited by 867 · cited 1×
“4 subunits, encoded by the KCNQ4 gene, regulate the excitability of sensory outer hair cells within the cochlea, playing an important role in hearing, and KCNQ4 pathogenic variants are responsible for autosomal dominant type 2 deafness, a progressive form of sensorineural hearing loss [44].”
Neuronal KCNQ potassium channels:physislogy and role in disease
Jentsch, T. J. (2000) · Nature Reviews Neuroscience · doi:10.1038/35036198 · Cited by 849
Voltage-gated potassium channels as therapeutic targets
Wulff, H., Castle, N. A., & Pardo, L. A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2983 · Cited by 799 · cited 1×
“Such functional diversity parallels a remarkable genetic and structural heterogeneity [15, 16].”
Physiological Roles of Aquaporin-4 in Brain
Nagelhus, E. A., & Ottersen, O. P. (2013) · Physiological Reviews · doi:10.1152/physrev.00011.2013 · Cited by 766 · cited 1×
“Beside these roles in neurons, K + channels participate in solute transport across endothelial cells [12] and to glial cells K + clearance from brain interstitial spaces [13].”
Pathways modulating neural KCNQ/M (Kv7) potassium channels
Delmas, P., & Brown, D. A. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1785 · Cited by 686 · cited 1×
“Additional I KM modulatory pathways, possibly exploited by other neurotransmitters, may also exist [28].”
Pan, Z., Kao, T., Horvath, Z., Lemos, J., Sul, J.-Y., Cranstoun, S. D., Bennett, V., Scherer, S. S., & Cooper, E. C. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4314-05.2006 · Cited by 585 · cited 1×
“On the basis of these data, it has been suggested that Kv7 clustering near voltage-dependent Na + channels at the axon initial segment [38] or at Ranvier nodes [39] serves specific and context-dependent roles, both restraining initiation and enhancing conduction of the action potential [36].”
Calcium-sensitive potassium channelopathy in human epilepsy and paroxysmal movement disorder
Du, W., Bautista, J. F., Yang, H., Diez-Sampedro, A., You, S.-A., Wang, L., Kotagal, P., Lüders, H. O., Shi, J., Cui, J., et al. (2005) · Nature Genetics · doi:10.1038/ng1585 · Cited by 574 · cited 1×
“…(b) a recurrent neuron–astrocyte–neuron excitatory loop [9], (c) faster action potentials repolarization and sodium (Na + ) channels repriming caused by hyperactivation of BK channels [10], or (d) hyperpolarization-activated nonselective cation currents [11], resulting in secondary depolarization.”
Spermine and Spermidine as Gating Molecules for Inward Rectifier K + Channels
Ficker, E., Taglialatela, M., Wible, B. A., Henley, C. M., & Brown, A. M. (1994) · Science · doi:10.1126/science.7973666 · Cited by 522
Self-citationDevaux, J. J., Kleopa, K. A., Cooper, E. C., & Scherer, S. S. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4512-03.2004 · Cited by 450 · cited 1×
“On the basis of these data, it has been suggested that Kv7 clustering near voltage-dependent Na + channels at the axon initial segment [38] or at Ranvier nodes [39] serves specific and context-dependent roles, both restraining initiation and enhancing conduction of the action potential [36].”
Origin and blockade of the synaptic responses of curarized sympathetic ganglia
Eccles, R. M., & Libet, B. (1961) · The Journal of Physiology · doi:10.1113/jphysiol.1961.sp006738 · Cited by 428 · cited 1×
“In these neurons, acetylcholine released from preganglionic cells triggers fast nicotinic excitatory postsynaptic potentials (fEPSPs) as well as slow excitatory membrane responses (sEPSPs) [21].”
KCNQ5, a Novel Potassium Channel Broadly Expressed in Brain, Mediates M-type Currents
Schroeder, B. C., Hechenberger, M., Weinreich, F., Kubisch, C., & Jentsch, T. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003245200 · Cited by 387 · cited 1×
“5 subunits, encoded by the KCNQ5 gene [49, 50], are preferentially expressed in neurons where they contribute to I KM heterogeneity in selected brain regions or neuronal subpopulations [51].”
KCNQ/M Channels Control Spike Afterdepolarization and Burst Generation in Hippocampal Neurons
Yue, C., & Yaari, Y. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0765-04.2004 · Cited by 369 · cited 1×
“I KM activates during spike afterdepolarization and limits spike duration, thereby preventing the spike from progressing into a burst [27].”
Gu, N., Vervaeke, K., Hu, H., & Storm, J. F. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2005.086835 · Cited by 363 · cited 1×
“…perisomatic region contribute to the medium and the slow components of the afterhyperpolarization current that follows the action potential and determines the refractory period and neuronal discharge frequency in response to sustained stimuli, a phenomenon known as spike-frequency adaptation [37].”
Marrion, N. V. (1997) · Annual Review of Physiology · doi:10.1146/annurev.physiol.59.1.483 · Cited by 350 · cited 1×
“Conductances with biophysical characteristics similar (if not identical) to those of I KM were later identified in other neurons, including mammalian hippocampal and cortical pyramidal cells [25].”
Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet
Rogawski, M. A., Löscher, W., & Rho, J. M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a022780 · Cited by 336 · cited 2×
“1 channels [87].”
Retigabine, A Novel Anti-Convulsant, Enhances Activation of KCNQ2/Q3 Potassium Channels
Wickenden, A. D., Yu, W., Zou, A., Jegla, T., & Wagoner, P. K. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12425-x · Cited by 320
Gunthorpe, M. J., Large, C. H., & Sankar, R. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2011.03365.x · Cited by 319 · cited 2×
“3 activation required to cause a clinically significant seizure reduction is 4 mV [84], azetukalner was estimated to be approximately 50 times more potent than ezogabine [136].”
Early and effective treatment of KCNQ 2 encephalopathy
Pisano, T., Numis, A. L., Heavin, S. B., Weckhuysen, S., Angriman, M., Suls, A., Podesta, B., Thibert, R. L., Shapiro, K. A., Guerrini, R., et al. (2015) · Epilepsia · doi:10.1111/epi.12984 · Cited by 301 · cited 1×
“Data are from the Protein Data Bank (7CR2) [56, 60] Seizures may respond to sodium channel blockers [64, 65]; although epilepsy may remit over time, moderate to severe neurodevelopment impairment typically persists.”
Structure of potassium channels
Kuang, Q., Purhonen, P., & Hebert, H. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1948-5 · Cited by 291 · cited 1×
“Such functional diversity parallels a remarkable genetic and structural heterogeneity [15, 16].”
Lerche, C., Scherer, C. R., Seebohm, G., Derst, C., Wei, A. D., Busch, A. E., & Steinmeyer, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002378200 · Cited by 277 · cited 1×
“5 subunits, encoded by the KCNQ5 gene [49, 50], are preferentially expressed in neurons where they contribute to I KM heterogeneity in selected brain regions or neuronal subpopulations [51].”
Dominant‐negative effects of KCNQ2 mutations are associated with epileptic encephalopathy
Orhan, G., Bock, M., Schepers, D., Ilina, E. I., Reichel, S. N., Löffler, H., Jezutkovic, N., Weckhuysen, S., Mandelstam, S., Suls, A., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24080 · Cited by 276 · cited 2×
“2) variants associated with seizures and epilepsy [72, 89, 90].”
Astrocytic modulation of neuronal excitability through K + spatial buffering
Bellot-Saez, A., Kékesi, O., Morley, J. W., & Buskila, Y. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.03.002 · Cited by 263
Psychiatric Comorbidities in People With Epilepsy
Mula, M., Kanner, A. M., Jetté, N., & Sander, J. W. (2021) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000000874 · Cited by 256 · cited 1×
“Depression is a common comorbidity in patients with epilepsy, and is also an adverse effect associated with commonly used ASMs [195].”
Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI)
Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2013) · Epilepsy Research · doi:10.1016/j.eplepsyres.2012.10.001 · Cited by 243
Self-citationKCNQ2 encephalopathy: Features, mutational hot spots, and ezogabine treatment of 11 patients
Millichap, J. J., Park, K. L., Tsuchida, T., Ben-Zeev, B., Carmant, L., Flamini, R., Joshi, N., Levisohn, P. M., Marsh, E., Nangia, S., et al. (2016) · Neurology Genetics · doi:10.1212/nxg.0000000000000096 · Cited by 241
Self-citationD-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures
Rostock, A., Tober, C., Rundfeldt, C., Bartsch, R., Engel, J., Polymeropoulos, E. E., Kutscher, B., Löscher, W., Hönack, D., White, H. S., et al. (1996) · Epilepsy Research · doi:10.1016/0920-1211(95)00101-8 · Cited by 240 · cited 3×
“2), was identified from quantitative structure-activity relationship (QSAR) studies on derivatives of the analgesic drug flupirtine, which had demonstrated anticonvulsant activity in screening tests [77].”
Trimmer, J. S. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.042 · Cited by 235 · cited 1×
“Further, electrophysiological studies have revealed that K + channels are the largest and most functionally heterogeneous class of ion channels, and that they are expressed in all eukaryotic cells and in prokaryotes [14].”
Potassium accumulation in interstitial space during epileptiform seizures
Fertziger, A. P., & Ranck, J. B. (1970) · Experimental Neurology · doi:10.1016/0014-4886(70)90150-0 · Cited by 221 · cited 2×
“The “K + accumulation hypothesis” postulates that a high [K + ] o is sufficient to trigger neuronal depolarization coupled with an increased firing rate, leading in turn to further increase in [K + ] o [3].”
Weight, F. F., & Votava, J. (1970) · Science · doi:10.1126/science.170.3959.755 · Cited by 209 · cited 2×
“While fEPSPs are typically generated by a transient increase in postsynaptic membrane conductance, sEPSPs are associated with a decrease in membrane conductance [22] caused by inactivation of a K + current [23].”
Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures
Porter, R. J., Partiot, A., Sachdeo, R., Nohria, V., & Alves, W. M. (2007) · Neurology · doi:10.1212/01.wnl.0000259034.45049.00 · Cited by 204 · cited 6×
“The proportion of patients who discontinued study medication due to treatment-emerging adverse events (TEAEs) ranged from 8 to 12% in the placebo group, 17% in the 600 mg/day group, 20–26% in the 900 mg/day group, and 27–29% in the 1200 mg/day group [111–113].”
InfluentialThe Concise Guide to PHARMACOLOGY 2023/24: Ion channels
Alexander, S. P. H., Mathie, A. A., Peters, J. A., Veale, E. L., Striessnig, J., Kelly, E., Armstrong, J. F., Faccenda, E., Harding, S. D., Davies, J. A., et al. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16178 · Cited by 198
Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy
Brodie, M. J., Lerche, H., Gil-Nagel, A., Elger, C., Hall, S., Shin, P., Nohria, V., Mansbach, H., & On behalf of the RESTORE 2 Study Group (2010) · Neurology · doi:10.1212/wnl.0b013e3181fd6170 · Cited by 192
Miceli, F., Soldovieri, M. V., Ambrosino, P., Barrese, V., Migliore, M., Cilio, M. R., & Taglialatela, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216867110 · Cited by 188
Self-citationRandomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy
French, J. A., Abou-Khalil, B. W., Leroy, R. F., Yacubian, E. M. T., Shin, P., Hall, S., Mansbach, H., & Nohria, V. (2011) · Neurology · doi:10.1212/wnl.0b013e3182194bd3 · Cited by 186
Battefeld, A., Tran, B. T., Gavrilis, J., Cooper, E. C., & Kole, M. H. P. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.4206-13.2014 · Cited by 180 · cited 2×
“Somatodendritic Kv7 channels are strongly activated by the backpropagating action potential and attenuate after-depolarization and repetitive firing [36].”
Martire, M., Castaldo, P., D'Amico, M., Preziosi, P., Annunziato, L., & Taglialatela, M. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3143-03.2004 · Cited by 175 · cited 1×
“Finally, Kv7 channels also modulate neurotransmitter release by controlling presynaptic terminal membrane potential, which in turn controls presynaptic Ca 2+ influx mediated by voltage-gated Ca 2+ channels [40, 41].”
Self-citationThe new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells
Rundfeldt, C. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01249-1 · Cited by 173 · cited 2×
“Although the clinical relevance of ezogabine’s GABAergic action has been questioned [81–86], in other experiments GABAergic effects have also been reported to occur at ezogabine concentrations as low as 1 µmol/L [91], and the possibility of GABA A receptor modulation contributing to the antiseizure…”
Driving With No Brakes: Molecular Pathophysiology of Kv7 Potassium Channels
Soldovieri, M. V., Miceli, F., & Taglialatela, M. (2011) · Physiology · doi:10.1152/physiol.00009.2011 · Cited by 164 · cited 3×
“1 has also been detected in non-cardiac tissues, such as the inner ear, thyroid gland, lung, gastrointestinal tract, small intestine, pancreas, ovaries, forebrain neuronal networks, and brainstem nuclei [26].”
InfluentialSelf-citationSelyanko, A. A., Hadley, J. K., Wood, I. C., Abogadie, F. C., Jentsch, T. J., & Brown, D. A. (2000) · The Journal of Physiology · doi:10.1111/j.1469-7793.2000.t01-2-00349.x · Cited by 162 · cited 1×
“When co-expressed in frog oocytes, KCNQ2 and KCNQ3 yield voltage-gated K + currents with biophysical and pharmacological properties identical to those of the M-current [31, 32], suggesting that the native ganglionic I KM is carried by an heterotetramer of Kv7.”
Potassium Channel Gain of Function in Epilepsy: An Unresolved Paradox
Niday, Z., & Tzingounis, A. V. (2018) · The Neuroscientist · doi:10.1177/1073858418763752 · Cited by 155 · cited 2×
“…mechanisms by which loss-and gain-of-function KCNQ2 , KCNQ3 , and KCNQ5 variants affect neurodevelopment and epileptogenesis are unclear [8, 35], the relationship between clinical phenotype/severity and variant-dependent extent of functional derangement in vitro provides a conceptual…”
New epilepsy therapies in development
Klein, P., Kaminski, R. M., Koepp, M., & Löscher, W. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00981-w · Cited by 154 · cited 1×
“2/3 activator from China [169, 170].”
Bialer, M., Johannessen, S. I., Koepp, M. J., Levy, R. H., Perucca, E., Perucca, P., Tomson, T., & White, H. S. (2020) · Epilepsia · doi:10.1111/epi.16725 · Cited by 148 · cited 6×
“Steady state (defined as no statistical difference between trough levels on successive days) is reached after 7–10 days, even though complete steady state is expected to occur after about 3 weeks [137].”
InfluentialSelf-citationGeneration of slow postsynaptic potentials without increases in ionic conductance.
Kobayashi, H., & Libet, B. (1968) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.60.4.1304 · Cited by 146 · cited 1×
“While fEPSPs are typically generated by a transient increase in postsynaptic membrane conductance, sEPSPs are associated with a decrease in membrane conductance [22] caused by inactivation of a K + current [23].”
Molecular basis for ligand activation of the human KCNQ2 channel
Li, X., Zhang, Q., Guo, P., Fu, J., Mei, L., Lv, D., Wang, J., Lai, D., Ye, S., Yang, H., et al. (2020) · Cell Research · doi:10.1038/s41422-020-00410-8 · Cited by 143 · cited 3×
“Data are from the Protein Data Bank (7CR2) [56, 60] Seizures may respond to sodium channel blockers [64, 65]; although epilepsy may remit over time, moderate to severe neurodevelopment impairment typically persists.”
Tzingounis, A. V., Heidenreich, M., Kharkovets, T., Spitzmaul, G., Jensen, H. S., Nicoll, R. A., & Jentsch, T. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004644107 · Cited by 141 · cited 1×
“5 subunits, encoded by the KCNQ5 gene [49, 50], are preferentially expressed in neurons where they contribute to I KM heterogeneity in selected brain regions or neuronal subpopulations [51].”
D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures
Tober, C., Rostock, A., Rundfeldt, C., & Bartsch, R. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00073-8 · Cited by 139 · cited 1×
“In particular, an increased threshold for induction of afterdischarges in kindled rats is already seen after i.p. and oral doses as low as 0.01 mg/kg, which are below those required to increase the threshold for induction of tonic hindlimb extension in the rat MES test [99].”
InfluentialKCNQ-Encoded Potassium Channels as Therapeutic Targets
Barrese, V., Stott, J. B., & Greenwood, I. A. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052912 · Cited by 137 · cited 3×
“3 channels for the treatment of seizure disorders and other indications, such as pain, affective disorders, and overactive bladder syndrome [45, 46, 173–175], a number of novel activators of these channels have recently been described, including SF0034 [176], ZG1732 and ZG2083 [177], RL-81 [178],…”
Bialer, M., Johannessen, S. I., Koepp, M. J., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2018) · Epilepsia · doi:10.1111/epi.14557 · Cited by 137 · cited 6×
“At in vitro concentrations of 3 μmol/L, which are much higher than those anticipated to be clinically efficacious, azetukalner did not cause direct inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, nor did it cause time ‐ dependent inhibition [136].”
InfluentialSelf-citationRapid and safe response to low‐dose carbamazepine in neonatal epilepsy
Sands, T. T., Balestri, M., Bellini, G., Mulkey, S. B., Danhaive, O., Bakken, E. H., Taglialatela, M., Oldham, M. S., Vigevano, F., Holmes, G. L., et al. (2016) · Epilepsia · doi:10.1111/epi.13596 · Cited by 135 · cited 1×
“Data are from the Protein Data Bank (7CR2) [56, 60] Seizures may respond to sodium channel blockers [64, 65]; although epilepsy may remit over time, moderate to severe neurodevelopment impairment typically persists.”
Self-citationLehman, A., Thouta, S., Mancini, G. M. S., Naidu, S., van Slegtenhorst, M., McWalter, K. M., Person, R., Mwenifumbo, J. C., Salvarinova, R., Guella, I., et al. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.05.016 · Cited by 133 · cited 3×
“De novo heterozygous missense mutations in KCNQ5 have been described in patients with neurodevelopmental disorders with or without epilepsy [52, 53].”
InfluentialSicca, F., Imbrici, P., D'Adamo, M. C., Moro, F., Bonatti, F., Brovedani, P., Grottesi, A., Guerrini, R., Masi, G., Santorelli, F. M., et al. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.03.016 · Cited by 126
Hadley, J. K., Passmore, G. M., Tatulian, L., Al-Qatari, M., Ye, F., Wickenden, A. D., & Brown, D. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-12-05012.2003 · Cited by 125 · cited 1×
“3 subunits [33].”
Epileptic channelopathies caused by neuronal Kv7 (KCNQ) channel dysfunction
Nappi, P., Miceli, F., Soldovieri, M. V., Ambrosino, P., Barrese, V., & Taglialatela, M. (2020) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-020-02404-2 · Cited by 123 · cited 1×
“With respect to functional changes, most SeLNE-causing KCNQ2 missense variants display a mild loss of function [70], pointing to haploinsufficiency as the main pathogenetic mechanism.”
Self-citationC‐terminus determinants for Mg2+ and polyamine block of the inward rectifier K+ channel IRK1.
Taglialatela, M., Ficker, E. K., Wible, B. A., & Brown, A. M. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00240.x · Cited by 120 · cited 1×
“Inward-rectifying channels drive currents inward (into the cell) more easily than outward because of a high-affinity block by endogenous intracellular polyamines and magnesium ions that plug the channel pore at positive potentials [19, 20].”
Self-citationRundfeldt, C., & Netzer, R. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1300346 · Cited by 116
Autism and developmental disability caused by KCNQ3 gain‐of‐function variants
Sands, T. T., Miceli, F., Lesca, G., Beck, A. E., Sadleir, L. G., Arrington, D. K., Schönewolf‐Greulich, B., Moutton, S., Lauritano, A., Nappi, P., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25522 · Cited by 115 · cited 1×
“A similar phenotype of developmental delay, autism spectrum disorder, and frequent sleep-activated multifocal epileptiform discharges has been described in association to gain-of-function KCNQ3 variants [75].”
Self-citationKV7 potassium channels: a new therapeutic target in smooth muscle disorders
Stott, J. B., Jepps, T. A., & Greenwood, I. A. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.12.003 · Cited by 111
Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2017) · Epilepsia · doi:10.1111/epi.13634 · Cited by 110
Self-citationMulkey, S. B., Ben‐Zeev, B., Nicolai, J., Carroll, J. L., Grønborg, S., Jiang, Y., Joshi, N., Kelly, M., Koolen, D. A., Mikati, M. A., et al. (2017) · Epilepsia · doi:10.1111/epi.13676 · Cited by 108 · cited 1×
“…variants have been reported in a small subset of patients with distinct neurodevelopmental disorders, including infantile spasms without prior neonatal seizures [73], or severe neonatal-onset encephalopathy with prominent startle-like myoclonus and a burst-suppression EEG pattern [74].”
Self-citationKalappa, B. I., Soh, H., Duignan, K. M., Furuya, T., Edwards, S., Tzingounis, A. V., & Tzounopoulos, T. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.5176-14.2015 · Cited by 105 · cited 1×
“…and overactive bladder syndrome [45, 46, 173–175], a number of novel activators of these channels have recently been described, including SF0034 [176], ZG1732 and ZG2083 [177], RL-81 [178], Lu AA41178 ( N -(2,4-dimethyl-6-morpholin-4-yl-pyridin-3-yl)−3,3-dimethylbutyramide) [179, 180], ETX-123…”
Millichap, J. J., Miceli, F., De Maria, M., Keator, C., Joshi, N., Tran, B., Soldovieri, M. V., Ambrosino, P., Shashi, V., Mikati, M. A., et al. (2017) · Epilepsia · doi:10.1111/epi.13601 · Cited by 103 · cited 1×
“…variants have been reported in a small subset of patients with distinct neurodevelopmental disorders, including infantile spasms without prior neonatal seizures [73], or severe neonatal-onset encephalopathy with prominent startle-like myoclonus and a burst-suppression EEG pattern [74].”
Self-citationAxon initial segment dysfunction in epilepsy
Wimmer, V. C., Reid, C. A., So, E. Y.-W., Berkovic, S. F., & Petrou, S. (2010) · The Journal of Physiology · doi:10.1113/jphysiol.2010.188417 · Cited by 93 · cited 1×
“Channels selectively permeable to K + (K + channels) are critical for K + homeostasis at distinct cellular locations in the brain [5, 6], and also at distinct subcellular regions (dendrites, soma, axons, axon initial segment) within specific neurons [7].”
Structural Basis for the Modulation of Human KCNQ4 by Small-Molecule Drugs
Li, T., Wu, K., Yue, Z., Wang, Y., Zhang, F., & Shen, H. (2021) · Molecular Cell · doi:10.1016/j.molcel.2020.10.037 · Cited by 92 · cited 1×
“4 [57, 58] have enhanced our understanding of key biophysical mechanisms such as voltage sensing, electromechanical coupling between the VSD and the gating machinery, permeation, and selectivity.”
Metabolism of Retigabine (D-23129), a Novel Anticonvulsant
Hempel, R., Schupke, H., McNeilly, P. J., Heinecke, K., Kronbach, C., Grunwald, C., Zimmermann, G., Griesinger, C., Engel, J., & Kronbach, T. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15258-0 · Cited by 90 · cited 1×
“Its steady-state volume of distribution estimated after intravenous administration is about 2–3 L/kg. Ezogabine is cleared by urinary excretion (about 35% of the dose) and by N -acetylation and subsequent N -glucuronidation [107].”
Structural insights into the lipid and ligand regulation of a human neuronal KCNQ channel
Zheng, Y. Y., Liu, H., Chen, Y., Dong, S., Wang, F., Wang, S., Li, G., Shu, Y., & Xu, F. (2021) · Neuron · doi:10.1016/j.neuron.2021.10.029 · Cited by 88 · cited 2×
“4 [57, 58] have enhanced our understanding of key biophysical mechanisms such as voltage sensing, electromechanical coupling between the VSD and the gating machinery, permeation, and selectivity.”
Blue-Gray Mucocutaneous Discoloration: A New Adverse Effect of Ezogabine
Garin Shkolnik, T., Feuerman, H., Didkovsky, E., Kaplan, I., Bergman, R., Pavlovsky, L., & Hodak, E. (2014) · JAMA Dermatology · doi:10.1001/jamadermatol.2013.8895 · Cited by 86
Multiple‐Dose, Linear, Dose‐Proportional Pharmacokinetics of Retigabine in Healthy Volunteers
Ferron‐Brady, G., Paul, J., Fruncillo, R. J., Richards, L. S., Knebel, N. G., Getsy, J. A., & Troy, S. M. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/00912700222011210 · Cited by 86 · cited 3×
“The pharmacokinetics of ezogabine is linear after single oral doses up to 600 mg and multiple dosing up to 1200 mg/day [101].”
InfluentialThe Role of Kv7.2 in Neurodevelopment: Insights and Gaps in Our Understanding
Dirkx, N., Miceli, F., Taglialatela, M., & Weckhuysen, S. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.570588 · Cited by 84 · cited 2×
“3 homomers depending on factors such as developmental stage, brain regions, cell types, subcellular region, and disease states [34, 35].”
Self-citationIhara, Y., Tomonoh, Y., Deshimaru, M., Zhang, B., Uchida, T., Ishii, A., & Hirose, S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0150095 · Cited by 83 · cited 1×
“2) variants associated with seizures and epilepsy [72, 89, 90].”
Iannotti, F. A., Panza, E., Barrese, V., Viggiano, D., Soldovieri, M. V., & Taglialatela, M. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162800 · Cited by 81 · cited 1×
“…been detected in vascular and visceral smooth muscle (including detrusor smooth muscle cells), with profound effects on basal tone and response to myogenic stimuli [45, 46], and in skeletal muscle cells, where they control proliferation, differentiation, and response to myotoxic stimuli [47, 48].”
Self-citationThe therapeutic potential of neuronal KCNQ channel modulators
Gribkoff, V. K. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.6.737 · Cited by 81 · cited 2×
“3 channels for the treatment of seizure disorders and other indications, such as pain, affective disorders, and overactive bladder syndrome [45, 46, 173–175], a number of novel activators of these channels have recently been described, including SF0034 [176], ZG1732 and ZG2083 [177], RL-81 [178],…”
Peretz, A., Sheinin, A., Yue, C., Degani-Katzav, N., Gibor, G., Nachman, R., Gopin, A., Tam, E., Shabat, D., Yaari, Y., et al. (2007) · Journal of Neurophysiology · doi:10.1152/jn.00634.2006 · Cited by 78
Diagnostic yield of targeted massively parallel sequencing in children with epileptic encephalopathy
Kothur, K., Holman, K., Farnsworth, E., Ho, G., Lorentzos, M., Troedson, C., Gupta, S., Webster, R., Procopis, P. G., Menezes, M. P., et al. (2018) · Seizure · doi:10.1016/j.seizure.2018.05.005 · Cited by 77 · cited 1×
“By contrast, homozygous frameshift mutations in KCNQ3 may be compatible with life, although associated with severe phenotypes with neonatal-onset epilepsy and non syndromic intellectual disability [68, 69].”
Novel Medications for Epilepsy
Fattore, C., & Perucca, E. (2011) · Drugs · doi:10.2165/11594640-000000000-00000 · Cited by 76 · cited 3×
“Ezogabine does not induce or inhibit the major cytochrome P450 (CYP) enzymes at clinically relevant concentrations, and it does not affect the plasma levels of concurrently administered CYP substrates [103, 108].”
Self-citationKCNQs: Ligand- and Voltage-Gated Potassium Channels
Abbott, G. W. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00583 · Cited by 74 · cited 1×
“This conformational shift is transmitted to the pore module via the S4–S5 linker and other interactions between elements of the pore module and S4 [54].”
URODYNAMIC EFFECTS OF THE K+ CHANNEL (KCNQ) OPENER RETIGABINE IN FREELY MOVING, CONSCIOUS RATS
Streng, T., Christoph, T., & Andersson, K. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000138155.33749.f4 · Cited by 73 · cited 1×
“Activation of Kv7 channels in sensory neurons [121] and urinary bladder smooth muscle [122] inhibits bladder contractility and may lead to urinary retention [123].”
Roeloffs, R., Wickenden, A. D., Crean, C. S., Werness, S., McNaughton-Smith, G. A., Stables, J. P., McNamara, J. O., Ghodadra, N., & Rigdon, G. C. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.137794 · Cited by 69
Potassium dynamics and seizures: Why is potassium ictogenic?
de Curtis, M., Uva, L., Gnatkovsky, V., & Librizzi, L. (2018) · Epilepsy Research · doi:10.1016/j.eplepsyres.2018.04.005 · Cited by 67
New antiepileptic medication linked to blue discoloration of the skin and eyes
Clark, S., Antell, A., & Kaufman, K. (2015) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098614560736 · Cited by 66 · cited 1×
“The use of ezogabine declined markedly after it was found to cause retinal changes and a bluish discoloration of skin and mucosae [124–126].”
Synthesis and Evaluation of Potent KCNQ2/3-Specific Channel Activators
Kumar, M., Reed, N. L., Liu, R., Aizenman, E., Wipf, P., & Tzounopoulos, T. (2016) · Molecular Pharmacology · doi:10.1124/mol.115.103200 · Cited by 65 · cited 1×
“…46, 173–175], a number of novel activators of these channels have recently been described, including SF0034 [176], ZG1732 and ZG2083 [177], RL-81 [178], Lu AA41178 ( N -(2,4-dimethyl-6-morpholin-4-yl-pyridin-3-yl)−3,3-dimethylbutyramide) [179, 180], ETX-123 [181], 1025c ( N,N ′…”
Groseclose, M. R., & Castellino, S. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.8b00313 · Cited by 62 · cited 2×
“Azetukalner lacks a secondary aniline structure and reportedly does not generate the phenazinium dimers considered to be responsible for ezogabine-induced pigmentation [129, 138, 140].”
Potassium channels and epilepsy
Gao, K., Lin, Z., Wen, S., & Jiang, Y. (2022) · Acta Neurologica Scandinavica · doi:10.1111/ane.13695 · Cited by 62 · cited 2×
“Channels selectively permeable to K + (K + channels) are critical for K + homeostasis at distinct cellular locations in the brain [5, 6], and also at distinct subcellular regions (dendrites, soma, axons, axon initial segment) within specific neurons [7].”
French, J. A., Porter, R. J., Perucca, E., Brodie, M. J., Rogawski, M. A., Pimstone, S., Aycardi, E., Harden, C., Qian, J., Rosenblut, C. L., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.3542 · Cited by 60
Self-citationRupprecht, R., Pradhan, A. K., Kufner, M., Brunner, L.-M., Nothdurfter, C., Wein, S., Schwarzbach, J. V., Puig-Bosch, X., Rupprecht, C., & Rammes, G. (2022) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-022-01532-3 · Cited by 53
Effects of age and sex on the disposition of retigabine
Hermann, R., Ferron‐Brady, G., Erb, K. A., Knebel, N. G., Ruus, P., Paul, J., Richards, L. S., Cnota, H., & Troy, S. M. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2003.12 · Cited by 52 · cited 3×
“In elderly individuals, the half-life is prolonged by about 30% and CL/F is reduced by about one-third [102].”
InfluentialVigil, F. A., Bozdemir, E., Bugay, V., Chun, S. H., Hobbs, M., Sanchez, I., Hastings, S. D., Veraza, R. J., Holstein, D. M., Sprague, S. M., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19857818 · Cited by 51 · cited 1×
“In a mouse model of traumatic brain injury (TBI), ezogabine administered intraperitoneally (i.p.) 30 min after the insult inhibited the cascade of events leading to neuronal hyperexcitability, seizures, blood brain dysfunction, brain inflammation, and cell death [97].”
Characterization of the K+ channel opening effect of the anticonvulsant retigabine in PC12 cells
Rundfeldt, C. (1999) · Epilepsy Research · doi:10.1016/s0920-1211(98)00131-4 · Cited by 50
Novel KCNQ2/Q3 Agonists as Potential Therapeutics for Epilepsy and Neuropathic Pain
Fritch, P. C., McNaughton-Smith, G. A., Amato, G. S., Burns, J. F., Eargle, C. W., Roeloffs, R., Harrison, W., Jones, L. S., & Wickenden, A. D. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901497b · Cited by 49
Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate
Zhang, Y.-M., Xu, H.-Y., Hu, H.-N., Tian, F.-Y., Chen, F., Liu, H.-N., Zhan, L., Pi, X.-P., Liu, J., Gao, Z.-B., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02252 · Cited by 49 · cited 4×
“7) is an ezogabine derivative developed at the Shanghai Institute of Materia Medica [165, 166].”
InfluentialIannotti, F. A., Barrese, V., Formisano, L., Miceli, F., & Taglialatela, M. (2013) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-12-1044 · Cited by 48 · cited 1×
“…been detected in vascular and visceral smooth muscle (including detrusor smooth muscle cells), with profound effects on basal tone and response to myogenic stimuli [45, 46], and in skeletal muscle cells, where they control proliferation, differentiation, and response to myotoxic stimuli [47, 48].”
Self-citationAmato, G., Roeloffs, R., Rigdon, G. C., Antonio, B., Mersch, T., McNaughton-Smith, G., Wickenden, A. D., Fritch, P., & Suto, M. J. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200053x · Cited by 48
The anticonvulsant retigabine is a subtype selective modulator of GABAAreceptors
Treven, M., Koenig, X., Assadpour, E., Gantumur, E., Meyer, C., Hilber, K., Boehm, S., & Kubista, H. (2015) · Epilepsia · doi:10.1111/epi.12950 · Cited by 48 · cited 2×
“The seizure suppressing effects were initially ascribed to potentiation of γ-aminobutyric acid (GABA)-mediated transmission [77], with more recent data indicating that the drug can an act as a subtype-selective modulator of extrasynaptic δ subunit-containing GABA A receptors [91].”
Brickel, N., Hewett, K., Rayner, K., McDonald, S., De'Ath, J., Daniluk, J., Joshi, K., Boll, M. C., Tiamkao, S., Vorobyeva, O., et al. (2020) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2019.106580 · Cited by 46 · cited 4×
“Macular vitelliform lesions have also been reported [104, 127].”
InfluentialLauritano, A., Moutton, S., Longobardi, E., Tran Mau‐Them, F., Laudati, G., Nappi, P., Soldovieri, M. V., Ambrosino, P., Cataldi, M., Jouan, T., et al. (2019) · Epilepsia Open · doi:10.1002/epi4.12353 · Cited by 45 · cited 1×
“By contrast, homozygous frameshift mutations in KCNQ3 may be compatible with life, although associated with severe phenotypes with neonatal-onset epilepsy and non syndromic intellectual disability [68, 69].”
Self-citationMusella, S., Carotenuto, L., Iraci, N., Baroli, G., Ciaglia, T., Nappi, P., Basilicata, M. G., Salviati, E., Barrese, V., Vestuto, V., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00911 · Cited by 45 · cited 2×
“…[182], SCR2682 (4-(2-bromo-6,7-dihydrothieno[3, 2-c]pyridin-5(4H)- yl)−2,6-dimethylphenyl)−3,3-dimethylbutanamide) [183], ZM-003 [184], several resin acid derivatives [185], sulfide analogs of flupirtine and ezogabine [186], and other ezogabine derivatives [131].”
Self-citationLigand activation mechanisms of human KCNQ2 channel
Ma, D., Zheng, Y., Li, X., Zhou, X., Yang, Z., Zhang, Y., Wang, L., Zhang, W., Fang, J., Zhao, G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42416-x · Cited by 44 · cited 1×
“2 [55, 56], and Kv7.”
Sequence determinants of subtype‐specific actions of KCNQ channel openers
Wang, A. W., Yang, R., & Kurata, H. T. (2017) · The Journal of Physiology · doi:10.1113/jp272762 · Cited by 43 · cited 1×
“…differences in the action of Kv7 activators, including state dependent activity, higher selectivity for specific Kv7 subtypes, and sensitivity to KCNQ mutations [61, 62, 199], as well as from the development of molecules combining Kv7 activation with other mechanisms of action [187, 190].”
TMS as a pharmacodynamic indicator of cortical activity of a novel anti‐epileptic drug, XEN1101
Premoli, I., Rossini, P. G., Goldberg, P., Posadas, K., Green, L., Yogo, N., Pimstone, S. N., Abela, E., Beatch, G. N., & Richardson, M. P. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50896 · Cited by 42
Flexible Stoichiometry: Implications for KCNQ2- and KCNQ3-Associated Neurodevelopmental Disorders
Springer, K., Varghese, N., & Tzingounis, A. V. (2021) · Developmental Neuroscience · doi:10.1159/000515495 · Cited by 40 · cited 1×
“3 homomers depending on factors such as developmental stage, brain regions, cell types, subcellular region, and disease states [34, 35].”
Benarroch, E. E. (2009) · Neurology · doi:10.1212/01.wnl.0000343739.72081.4e · Cited by 39
Nappi, M., Barrese, V., Carotenuto, L., Lesca, G., Labalme, A., Ville, D. M., Smol, T., Rama, M., Dieux‐Coëslier, A., Rivier-Ringenbach, C., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116887119 · Cited by 39
Self-citationBialer, M., Johannessen, S. I., Koepp, M. J., Levy, R. H., Perucca, E., Perucca, P., Tomson, T., & White, H. S. (2022) · Epilepsia · doi:10.1111/epi.17376 · Cited by 39 · cited 4×
“Azetukalner is cleared by CYP3A4-mediated metabolism, with other CYP enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6) playing little or no role [138].”
InfluentialSelf-citationKv7 Channels and Excitability Disorders
Jones, F., Gamper, N., & Gao, H. (2021) · Handbook of Experimental Pharmacology · doi:10.1007/164_2021_457 · Cited by 38
Metcalf, C. S., Huff, J. L., Thomson, K. E., Johnson, K. J., Edwards, S. F., & Wilcox, K. S. (2019) · Epilepsia Open · doi:10.1002/epi4.12354 · Cited by 34 · cited 1×
“Ezogabine given i.p. was also effective in the lamotrigine-resistant amygdala kindling rat model of drug-resistant focal epilepsy, with a median effective dose (ED50) of 3.2 [95% confidence interval (CI) 1.3–5.4] mg/ kg [100].”
InfluentialBialer, M., Johannessen, S. I., Koepp, M. J., Perucca, E., Perucca, P., Tomson, T., & White, H. S. (2024) · Epilepsia · doi:10.1111/epi.18075 · Cited by 34
Self-citationCurrent state of the epilepsy drug and device pipeline
Terman, S. W., Kirkpatrick, L. A., Akiyama, L. F., Baajour, W., Atilgan, D., Dorotan, M. K., Choi, H. W., & French, J. A. (2024) · Epilepsia · doi:10.1111/epi.17884 · Cited by 33 · cited 1×
“…ZG1732 and ZG2083 [177], RL-81 [178], Lu AA41178 ( N -(2,4-dimethyl-6-morpholin-4-yl-pyridin-3-yl)−3,3-dimethylbutyramide) [179, 180], ETX-123 [181], 1025c ( N,N ′ -{4-[(4-fluorobenzyl)(prop-2-yn-1-yl)amino]−1,2-phenylene}bis(3,3-dimethylbutanamide) [182], SCR2682…”
Bialer, M., Johannessen, S. I., Koepp, M. J., Perucca, E., Perucca, P., Tomson, T., & White, H. S. (2024) · Epilepsia · doi:10.1111/epi.18056 · Cited by 32
Self-citationKnight, D., Mahida, S., Kelly, M., Poduri, A., & Olson, H. E. (2023) · Epilepsia · doi:10.1111/epi.17627 · Cited by 31 · cited 2×
“2/3 variants [115].”
Evaluation of subchronic administration of antiseizure drugs in spontaneously seizing rats
Thomson, K. E., Metcalf, C. S., Newell, T. G., Huff, J. L., Edwards, S. F., West, P. J., & Wilcox, K. S. (2020) · Epilepsia · doi:10.1111/epi.16531 · Cited by 29 · cited 1×
“Other models where ezogabine is effective include spon-taneous seizures after kainate-induced status epilepticus in rats [94], organophosphate-induced status epilepticus [95], acute seizures induced by Theiler's murine encephalomyelitis virus infection in mice [96], and neuronal excitability and…”
Trenité, D. G. A. K.-N., Biton, V., French, J. A., Abou-Khalil, B. W., Rosenfeld, W. E., DiVentura, B. D., Moore, E. L., Hetherington, S., & Rigdon, G. C. (2013) · Epilepsia · doi:10.1111/epi.12224 · Cited by 28
Functional and behavioral signatures of Kv7 activator drug subtypes
Kanyo, R., Wang, C. K., Locskai, L. F., Li, J., Allison, W. T., & Kurata, H. T. (2020) · Epilepsia · doi:10.1111/epi.16592 · Cited by 28
Nissenkorn, A., Kornilov, P., Peretz, A. S., Blumkin, L., Heimer, G., Ben‐Zeev, B., & Attali, B. (2021) · Epileptic Disorders · doi:10.1684/epd.2021.1315 · Cited by 28
Metcalf, C. S., Vanegas, F., Underwood, T. K., Johnson, K. J., West, P. J., Smith, M. D., & Wilcox, K. S. (2021) · Epilepsia Open · doi:10.1002/epi4.12550 · Cited by 28
Clinical Pharmacokinetics of Retigabine/Ezogabine
Tompson, D. J., & Crean, C. S. (2013) · Current Clinical Pharmacology · doi:10.2174/15748847113089990053 · Cited by 27 · cited 1×
“Co-administration Co-administration with a high-fat meal does not affect the extent of absorption, but increases the peak plasma drug concentration by about 14% and 38% for the 200 and the 400 mg tablets, respectively, and delays the time to peak concentration by about 0.75 h [104, 105].”
InfluentialGil‐Nagel, A., Brodie, M. J., Leroy, R. F., Cyr, T., Hall, S. T., Castiglia, M., Twomey, C. K., & VanLandingham, K. (2012) · Epilepsy Research · doi:10.1016/j.eplepsyres.2012.05.007 · Cited by 27 · cited 3×
“In open-label extension studies, the improvement in seizure control associated with ezogabine was maintained during long-term treatment [114].”
Sulfide Analogues of Flupirtine and Retigabine with Nanomolar KV7.2/KV7.3 Channel Opening Activity
Bock, C., Surur, A. S., Beirow, K., Kindermann, M. K., Schulig, L., Bodtke, A., Bednarski, P. J., & Link, A. (2019) · ChemMedChem · doi:10.1002/cmdc.201900112 · Cited by 27
Untersuchungen zur Thermodynamik der bioelektrischen Ströme
Bernstein, J., & Tschermak, A. (1906) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/bf01676972 · Cited by 27
Plosker, G. L., & Scott, L. J. (2006) · CNS Drugs · doi:10.2165/00023210-200620070-00005 · Cited by 26
Seefeld, M. A., Lin, H., Holenz, J., Downie, D., Donovan, B., Fu, T., Pasikanti, K., Zhen, W., Cato, M., Chaudhary, K. W., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.09.036 · Cited by 26 · cited 2×
“The functional implications of these differences are not fully understood, and it unclear whether compounds with greater selectivity for specific Kv7 subtypes could reduce the risk of urinary symptoms while retaining antiseizure activity [175, 197, 198].”
Svalø, J., Sheykhzade, M., Nordling, J., Matras, C., & Bouchelouche, P. N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117350 · Cited by 25 · cited 3×
“The functional implications of these differences are not fully understood, and it unclear whether compounds with greater selectivity for specific Kv7 subtypes could reduce the risk of urinary symptoms while retaining antiseizure activity [175, 197, 198].”
Voltage-gated potassium channels KCNQs: Structures, mechanisms, and modulations
Huang, Y., Ma, D., Yang, Z., Zhao, Y., & Guo, J. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.149218 · Cited by 24 · cited 2×
“Data are from the Protein Data Bank (7CR2) [56, 60] Seizures may respond to sodium channel blockers [64, 65]; although epilepsy may remit over time, moderate to severe neurodevelopment impairment typically persists.”
Socała, K., Jakubiec, M., Abram, M., Mlost, J., Starowicz, K., Kamiński, R. M., Ciepiela, K., Andres‐Mach, M., Zagaja, M. P., Metcalf, C. S., et al. (2024) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2024.102634 · Cited by 24 · cited 1×
“Although to our knowledge these agents have not been evaluated for other indications, TRPV1 channels are also regarded as potential targets for the development of newer ASMs [191].”
Syeda, R., Santos, J. S., & Montal, M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.683185 · Cited by 23 · cited 1×
“The opening of Kv7 channels induced by ezogabine is associated with a shift of the voltage dependence for channel activation to more negative potentials [84, 88].”
Generaux, G. T., Lakhani, V., Yang, Y., Nadanaciva, S., Qiu, L., Riccardi, K. A., Di, L., Howell, B. A., Siler, S. Q., Watkins, P. B., et al. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.523 · Cited by 21 · cited 1×
“Further development, however, was terminated following discovery of liver toxicity in healthy subjects, an off-target effect ascribed to inhibition of liver mitochondrial function and bile salt export protein (BSEP) transport [163, 164].”
KV7 channels in the human detrusor: channel modulator effects and gene and protein expression
Bientinesi, R., Mancuso, C., Martire, M., Bassi, P. F., Sacco, E., & Currò, D. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1312-9 · Cited by 20
Ezogabine skin discoloration is reversible after discontinuation
Mathias, S. V., & Abou-Khalil, B. W. (2017) · Epilepsy & Behavior Case Reports · doi:10.1016/j.ebcr.2017.01.001 · Cited by 20 · cited 1×
“The discoloration can be slowly reversible in some patients after drug discontinuation [127, 132].”
Pore- and voltage sensor–targeted KCNQ openers have distinct state-dependent actions
Wang, C. K., Lamothe, S. M., Wang, A. W. T., Yang, R. Y., & Kurata, H. T. (2018) · The Journal of General Physiology · doi:10.1085/jgp.201812070 · Cited by 20 · cited 2×
“Of note, some Kv7 activators such as ezogabine interact with the pore region of the channel, whereas others such as ICA-069673 target the VSD region [61, 62].”
Tykocki, N. R., Heppner, T. J., Dalsgaard, T., Bonev, A. D., & Nelson, M. T. (2019) · The Journal of Physiology · doi:10.1113/jp277021 · Cited by 20
Vigil, F. A., Belchior, H., Bugay, V., Bazaldua, I. I., Stoja, A. P., Dantas, D. C., Chun, S. H., Farmer, A., Bozdemir, E., Holstein, D. M., et al. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01361-9 · Cited by 20
Grupe, M., Bentzen, B. H., Benned-Jensen, T., Nielsen, V., Frederiksen, K., Jensen, H. S., Jacobsen, A.-M., Skibsbye, L., Sams, A. G., Grunnet, M., et al. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173440 · Cited by 19 · cited 1×
“…including SF0034 [176], ZG1732 and ZG2083 [177], RL-81 [178], Lu AA41178 ( N -(2,4-dimethyl-6-morpholin-4-yl-pyridin-3-yl)−3,3-dimethylbutyramide) [179, 180], ETX-123 [181], 1025c ( N,N ′ -{4-[(4-fluorobenzyl)(prop-2-yn-1-yl)amino]−1,2-phenylene}bis(3,3-dimethylbutanamide) [182], SCR2682…”
Bloms-Funke, P., Bankstahl, M., Bankstahl, J., Kneip, C., Schröder, W., & Löscher, W. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108884 · Cited by 19 · cited 2×
“…differences in the action of Kv7 activators, including state dependent activity, higher selectivity for specific Kv7 subtypes, and sensitivity to KCNQ mutations [61, 62, 199], as well as from the development of molecules combining Kv7 activation with other mechanisms of action [187, 190].”
Wurm, K. W., Bartz, F., Schulig, L., Bodtke, A., Bednarski, P. J., & Link, A. (2022) · ChemMedChem · doi:10.1002/cmdc.202200262 · Cited by 19
Yang, G.-M., Tian, F., Shen, Y.-W., Yang, C., Yuan, H. L., Li, P., & Gao, Z. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01073-y · Cited by 19
Yue, J., Qiao, G.-H., Liu, N., Nan, F., & Gao, Z. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.142 · Cited by 17 · cited 1×
“…syndrome [45, 46, 173–175], a number of novel activators of these channels have recently been described, including SF0034 [176], ZG1732 and ZG2083 [177], RL-81 [178], Lu AA41178 ( N -(2,4-dimethyl-6-morpholin-4-yl-pyridin-3-yl)−3,3-dimethylbutyramide) [179, 180], ETX-123 [181], 1025c ( N,N ′…”
Long term retention of retigabine in a cohort of people with drug resistant epilepsy
Wehner, T., Chinnasami, S., Nový, J., Bell, G. S., Duncan, J. S., & Sander, J. W. A. S. (2014) · Seizure · doi:10.1016/j.seizure.2014.08.001 · Cited by 16 · cited 4×
“In open-label studies, the proportion of patients reporting urinary system symptoms (mostly voiding problems, leading at times to urinary retention and urinary tract infections) was around 9–14% [114, 119, 120].”
InfluentialWang, H., Qiao, Z., Luan, K., Xiang, W., Chang, X., Zhang, Y., Wei, N., & Wang, K. (2024) · Epilepsia · doi:10.1111/epi.18092 · Cited by 16 · cited 1×
“…[179, 180], ETX-123 [181], 1025c ( N,N ′ -{4-[(4-fluorobenzyl)(prop-2-yn-1-yl)amino]−1,2-phenylene}bis(3,3-dimethylbutanamide) [182], SCR2682 (4-(2-bromo-6,7-dihydrothieno[3, 2-c]pyridin-5(4H)- yl)−2,6-dimethylphenyl)−3,3-dimethylbutanamide) [183], ZM-003 [184], several resin…”
KCNQ3 is the principal target of retigabine in CA1 and subicular excitatory neurons
Varghese, N., Lauritano, A., Taglialatela, M., & Tzingounis, A. V. (2021) · Journal of Neurophysiology · doi:10.1152/jn.00564.2020 · Cited by 15
Self-citationBloms‐Funke, P., Schumacher, M., Liu, S., Su, D., Li, J., Lière, P., Rupprecht, R., Nothdurfter, C., Bahrenberg, G., Christoph, T., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174935 · Cited by 15 · cited 2×
“TSPO activators promote the synthesis of neurosteroids and exert a variety of other actions, which may translate into neuroprotective, neuroregenerative, anti-inflammatory, and possibly antidepressant effects [188, 189]; combining these properties with Kv7.”
Tian, F., Cao, B., Xu, H., Zhan, L., Nan, F., Li, N., Taglialatela, M., & Gao, Z. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105860 · Cited by 15 · cited 1×
“Prominent anticonvulsant activity was also observed in a mouse model carrying an epileptogenic KCNQ2 mutation [167].”
Self-citationCelentano, C., Carotenuto, L., Miceli, F., Carleo, G., Corrado, B., Baroli, G., Iervolino, S., Vecchione, R., Taglialatela, M., & Barrese, V. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00709.2023 · Cited by 15 · cited 1×
“Beside these roles in neurons, K + channels participate in solute transport across endothelial cells [12] and to glial cells K + clearance from brain interstitial spaces [13].”
Self-citationAizawa, N., Wakamatsu, D., Kida, J., Otsuki, T., Saito, Y., Matsuya, H., Homma, Y., & Igawa, Y. (2015) · Neurourology and Urodynamics · doi:10.1002/nau.22920 · Cited by 14 · cited 1×
“Because of the inhibiting effect of Kv7 activators on detrusor smooth muscle [46, 175], as well as on bladder sensory afferent nerve activity [121, 196], urinary retention may be considered a class effect of these medications.”
Nass, R. D., Kurth, C., Kull, A., Graf, W. D., Kasper, B. S., Hamer, H. M., Strzelczyk, A., Elger, C. E., Steinhoff, B. J., Surges, R., et al. (2016) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2015.12.034 · Cited by 14 · cited 3×
“In open-label studies, the proportion of patients reporting urinary system symptoms (mostly voiding problems, leading at times to urinary retention and urinary tract infections) was around 9–14% [114, 119, 120].”
Detrusor Smooth Muscle KV7 Channels: Emerging New Regulators of Urinary Bladder Function
Malysz, J., & Petkov, G. V. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.01004 · Cited by 14 · cited 4×
“3 channels for the treatment of seizure disorders and other indications, such as pain, affective disorders, and overactive bladder syndrome [45, 46, 173–175], a number of novel activators of these channels have recently been described, including SF0034 [176], ZG1732 and ZG2083 [177], RL-81 [178],…”
InfluentialA profile of azetukalner for the treatment of epilepsy: from pharmacology to potential for therapy
Lattanzi, S., Trinka, E., Meletti, S., Striano, P., Matricardi, S., Silvestrini, M., & Brigo, F. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2337012 · Cited by 14
Constitutive opening of the Kv7.2 pore activation gate causes KCNQ2 -developmental encephalopathy
Nappi, M., Alberini, G., Berselli, A., Roscioni, A., Soldovieri, M. V., Servettini, I., Barrese, V., Weckhuysen, S., Chiu, A. T. G., Scheffer, I. E., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2412388121 · Cited by 13 · cited 1×
“They also provided an atomistic resolution of channel regulation by mutations [59], endogenous ligands (PIP2 and calmodulin, in particular), and drugs, including the Kv7 activator ezogabine (Fig.”
Self-citationAleo, M. D., Aubrecht, J., Bonin, P. D., Burt, D. A., Colangelo, J. L., Luo, L., Schomaker, S., Swiss, R. L., Kirby, S., Rigdon, G. C., et al. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.467 · Cited by 12
The Interaction Potential of Retigabine (Ezogabine) with Other Antiepileptic Drugs
Tompson, D. J., & Crean, C. S. (2014) · Current Clinical Pharmacology · doi:10.2174/1574884708666131111192311 · Cited by 10 · cited 3×
“Ezogabine does not induce or inhibit the major cytochrome P450 (CYP) enzymes at clinically relevant concentrations, and it does not affect the plasma levels of concurrently administered CYP substrates [103, 108].”
Jiang, S., Liu, B., Lin, K., Li, L., Strochlic, T., Tan, S., Zhang, X., Jiang, L., Ni, H., Wang, Y., et al. (2023) · Hippocampus · doi:10.1002/hipo.23587 · Cited by 10 · cited 1×
“Specifically, downregulation of KCNQ2 and KCNQ3 transcript expression has been found in two publicly available databases of hippocampal samples from TLE patients [76].”
Zahra, A., Liu, R., Wang, J., & Wu, J. (2023) · Neurological Sciences · doi:10.1007/s10072-023-06955-x · Cited by 9 · cited 2×
“Although the clinical relevance of ezogabine’s GABAergic action has been questioned [81–86], in other experiments GABAergic effects have also been reported to occur at ezogabine concentrations as low as 1 µmol/L [91], and the possibility of GABA A receptor modulation contributing to the antiseizure…”
Awsare, B., Lerner, J. T., Ashbrenner, E., Sevinsky, H., Bozik, M. E., Dworetzky, S. I., Donahue, L., Killingsworth, R., Francoeur, B., & Qureshi, I. (2024) · Neurology · doi:10.1212/wnl.0000000000206409 · Cited by 9
The effect of ezogabine on the pharmacokinetics of an oral contraceptive agent
Crean, C. S., Tompson, D. J., & Buraglio, M. (2013) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp201916 · Cited by 8 · cited 1×
“Ezogabine (750 mg/day) did not affect the pharmacokinetics of an oral contraceptive containing ethinylestradiol and norethindrone, and there was no effect of the oral contraceptive on the pharmacokinetics of ezogabine [109].”
XEN1101: A Novel Potassium Channel Modulator for the Potential Treatment of Focal Epilepsy in Adults
Wang, T., & Krauss, G. L. (2022) · touchREVIEWS in Neurology · doi:10.17925/usn.2022.18.1.2 · Cited by 7 · cited 1×
“After multiple dosing, azetukalner elimination shows a late terminal phase with an average half-life of 4–10 days [136, 137, 143], which has been ascribed to slow release of the drug from tissue compartments [144].”
Barker, B. S., Spampanato, J. G., McCarren, H. S., Berger, K. E., Jackson, C. E., Yeung, D. T., Dudek, F. E., & McDonough, J. H. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.03.029 · Cited by 6
Ottosson, N. E., Ejneby, M. S., Wu, X., Estrada‐Mondragón, A., Nilsson, M., Karlsson, U., Schupp, M., Rognant, S., Jepps, T. A., Konradsson, P., et al. (2021) · Epilepsia · doi:10.1111/epi.16932 · Cited by 6
Namdari, R., Luzon, C., Cadieux, J. A., Leung, J., & Beatch, G. N. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00343-x · Cited by 6
Zhuang, X.-F., Liu, Y., Yang, Z.-H., Gao, Q. F., Wang, L., Ju, C., & Wang, K. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001328 · Cited by 6 · cited 1×
“…[182], SCR2682 (4-(2-bromo-6,7-dihydrothieno[3, 2-c]pyridin-5(4H)- yl)−2,6-dimethylphenyl)−3,3-dimethylbutanamide) [183], ZM-003 [184], several resin acid derivatives [185], sulfide analogs of flupirtine and ezogabine [186], and other ezogabine derivatives [131].”
Tompson, D. J., Crean, C. S., Buraglio, M., & Arumugham, T. (2014) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s64131 · Cited by 5 · cited 1×
“In a drug–drug interaction study in healthy subjects, however, ezogabine at doses up to 900–1200 mg/day caused only a small, non-dose-dependent and nonclinically relevant increase in digoxin area under the plasma drug concentration–time curve (AUC) [110].”
Wong, S., Liou, Y., Yang, J., & Lee, I. (2024) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2024.109798 · Cited by 5 · cited 1×
“2) variants associated with seizures and epilepsy [72, 89, 90].”
Wei, S., Weng, S., Cao‐wenjing, C., Huajun, Y., & Wang, Q. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70002 · Cited by 5
Raveh, A., Pen, Y., Silberman, A., Peretz, A. S., Attali, B., Maile, L., Davidson, S., Brown, A. D., Kennedy, J. D., & Belinson, H. (2024) · Pain · doi:10.1097/j.pain.0000000000003390 · Cited by 5 · cited 2×
“3 activation with modulation of the transient receptor potential vanilloid type 1 (TRPV1) ligand-gated ion channel [190].”
Three-Step Synthesis of the Antiepileptic Drug Candidate Pynegabine
Sun, Y.-J., Gong, Y., Lu, S., Zhang, S., & Xu, S. (2023) · Molecules · doi:10.3390/molecules28134888 · Cited by 3 · cited 1×
“7) is an ezogabine derivative developed at the Shanghai Institute of Materia Medica [165, 166].”
Characterization of BHV-7000: A Novel Kv7.2/7.3 Activator for the Treatment of Seizures (S29.006)
Picchione, K. E., Resnick, L., Bozik, M. E., & Dworetzky, S. I. (2024) · Neurology · doi:10.1212/wnl.0000000000206250 · Cited by 3
Retigabine: blue skin discoloration and retinal pigment abnormalities.
(2013) · PubMed · Cited by 2
French, J. A., Porter, R. J., Perucca, E., Brodie, M. J., Rogawski, M. A., Harden, C. L., Qian, J., Luzon, C., Kenney, C., & Beatch, G. N. (2024) · Neurology · doi:10.1212/wnl.0000000000204537 · Cited by 2
Self-citationLerner, J. T., Awsare, B., Sevinsky, H., Ashbrenner, E., Killingsworth, R., Kendrick, R., Vereycken, E., Colenbrier, N., Neuray, C., van Mierlo, P., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000206367 · Cited by 2
Porter, R. J., French, J. A., Perucca, E., Brodie, M. J., Harden, C. L., Luzon, C., Qian, J., Kenney, C., & Beatch, G. N. (2024) · Neurology · doi:10.1212/wnl.0000000000205867 · Cited by 1
Self-citationCONSTITUTIVE OPENING OF THE Kv7.2 PORE ACTIVATION GATE CAUSES KCNQ2 -DEVELOPMENTAL ENCEPHALOPATHYPreprint
Nappi, M., Alberini, G., Berselli, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.20.593680 · Cited by 1
Awsare, B., Lerner, J. T., Ashbrenner, E., Sevinsky, H., Bozik, M. E., Dworetzky, S. I., Donahue, L., Killingsworth, R., Francoeur, B., & Qureshi, I. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00401 · Cited by 1 · cited 1×
“In phase 1 studies, single doses of BHV-7000 up to 100 mg and multiple doses up to 60 mg b.i.d. for 15 days were well tolerated in healthy subjects [139, 156, 157].”
Lerner, J. T., Awsare, B., Sevinsky, H., Ashbrenner, E., Killingsworth, R., Kendrick, R., Vereycken, E., Colenbier, N., Neuray, C., van Mierlo, P., et al. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00402 · Cited by 1
Research works printed but not linked: 7
- Miceli F, Soldovieri MV, Weckhuysen S, et al. KCNQ2-Related Disorders. 2010 Apr 27 [Updated 2022 May 19]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. https://www.ncbi.nlm.nih.gov/books/NBK32534/.
- Pressler R, Taglialatela M, Plouin P, Hassn H. Self-limited (familial) neonatal epilepsy. In: Engel J Jr, Moshé SL, editors, Epilepsy. A Comprehensive Textbook, 3rd edition, Volume 3, Chapter 275, Philadephia: Wolters Kluwer 2024. p. 2817–26
- Tandy MD, Cadieux JA, Namdari R. Using modified QbD to develop a novel pediatric formulation of ezogabine. Pharm Technol. 2021;45:44–9. https://www.pharmtech.com/view/using-modified-qbd-to-develop-a-novelpediatric-formulation-of-ezogabine. Accessed 15 Aug 2024.
- Goldberg YP. XEN1101, a novel modulator of Kv7.2/3 for the treatment of epilepsy. Slide presentation at the Epilepsy Foundation Pipeline Conference, San Francisco, February 22-23, 2018. https://www.xenon-pharma.com/wp-content/uploads/2018/05/XEN1101_EpilepsyFoundationPresentation_February2018.pdf. Accessed 20 Aug 2024.
- French J, Porter R, Perucca E, Brodie M, Rogawski M, Harden C, Qian J, Rosenblut CL, Kenney C, Beatch GN. Axetukalner (XEN1101), a novel, potent, Kv7 potassium channel opener: Interim data from an ongoing, long-term open-label extension of a phase 2b study (X- TOLE) in adults with focal onset seizures. Poster presented at the 15th European Epilepsy Congress, September 7–11, 2024, Rome, Italy. https://www.xenon-pharma.com/wp-content/uploads/2024/09/EEC24French.pdfy. Accessed 22 Aug 2024. · DOI
- Picchione K, Resnick L, Bozik M, Dworetzky S. Characterization of BHV-7000: a novel Kv7.2/7.3 activator for the treatment of seizures. Presented at the American Academy of Neurology Annual Meeting, Denver, CO, April 13-18, 2024. Neurology 102 (suppl 1). https://doi.org/10.1212/WNL.0000000000206250. · DOI
- Adis International Ltd. CB 03. AdisInsight, updated 3 October 2024. https://adisinsight.springer.com/drugs/800057520. Accessed 20 Oct 2024.
Cited by
Recent advances in the pharmacology of voltage-gated ion channels
Mateos, D. L., Harris, B. J., Hernández-González, A., Yarov-Yarovoy, V. M., & Wulff, H. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100090 · Cited by 31
“142 After some attempts at repurposing of retigabine for ALS in a phase II clinic trial (NCT02450552), where it was shown to reduce cortical and spinal motor neuron hyperexcitability in ALS patients using transcranial magnetic stimulation, 143 or reformulation as XEN496 for KCNQ2 -related DEE and…”
InfluentialVoltage-Gated Ion Channels in Neuropathic Pain Signaling
Felix, R., Corzo-López, A., & Sandoval, A. (2025) · Life · doi:10.3390/life15060888 · Cited by 37
“Likewise, BHV-7000 is a late-stage drug candidate that selectively activates K V 7.2/7.3 potassium channels, primarily developed for epilepsy and mood disorders, with ongoing exploration for pain treatment [295].”
InfluentialPrecision therapies for genetic epilepsies in 2025: Promises and pitfalls
Wang, S., Perucca, E., Berkovic, S. F., & Perucca, P. (2025) · Epilepsia Open · doi:10.1002/epi4.70065 · Cited by 25
Self-citationLiu, X., Yu, Y., & Wang, Q. (2025) · Nonlinear Dynamics · doi:10.1007/s11071-025-11863-0 · Cited by 16
“Clinically, this framework suggests that therapeutic strategies targeting ionic regulation — particularly potassium channels and their associated pathways — may be as critical as synaptic interventions in controlling seizures [42].”
Current and emerging pharmacotherapies in Lennox-Gastaut syndrome
Samanta, D., & Nath, M. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2516630 · Cited by 14
“2) may be addressed by emerging potassium channel openers, including XEN1101 and BHV-7000 [73].”
Metadata
- Authors
- Perucca, E., & Taglialatela, M.
- Affiliations
- The University of Melbourne (AU)
- University of Naples Federico II (IT)
- Corresponding author
- Perucca, Emilio
- Venue
- CNS Drugs
- Published
- 2025-01-24
- Volume
- 39
- Issue
- 3
- Pages
- 263-288
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- PMC
- PMC11850491
- OpenAlex
- W4406801261
- Cited by
- 43
- References
- 179
- Citations by year
- 2026: 27 · 2025: 16
- FWCI
- 7.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- CNS Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
- Funders
- University of Melbourne
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
- Keywords
- Kv7 potassium channels, Kv7.2, Kv7.3, KCNQ2, epilepsy, antiepileptic drugs, retigabine, ezogabine, developmental and epileptic encephalopathy, major depressive disorder, generalized tonic-clonic seizures
- MeSH terms
- Animals, Anticonvulsants, Carbamates, Epilepsy, Humans, Phenylenediamines, KCNQ Potassium Channels, KCNQ2 Potassium Channel, KCNQ3 Potassium Channel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.